Clinic
Upmc Children's Hospital of Pittsburgh
Upmc Children's Hospital of Pittsburgh was paid $83.00M by Medicaid between Jan 2018 and Dec 2024, across 527 billing codes. Its largest line is 99284, emergency room visit (serious) — 14% of everything it billed.
33Billing provider infoUPMC CHILDREN'S HOSPITAL OF PITTSBURGH
PITTSBURGH, PA 15224
PITTSBURGH, PA 15224
33aNPI1164426896assigned 06/10/2005
33bProvider typeClinic/Center
28Total paid$83.00M
24GClaims1,042,961
24DCodes billed527
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Pennsylvania
Rank by total paid#3 of 176
Median peer was paid$441K
This provider vs. median188×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,011 | $1.93M | |
| 2019 | 19,511 | $1.51M | |
| 2020 | 99,963 | $7.66M | |
| 2021 | 462,940 | $39.60M | |
| 2022 | 154,246 | $11.52M | |
| 2023 | 143,189 | $10.79M | |
| 2024incomplete | 132,101 | $9.99M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 40,482 | 39,776 | $11.95M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 68,766 | 67,757 | $11.91M |
| G0378 | Hospital observation service, per hour | 9.1% | 10,241 | 6,239 | $7.54M |
| D2930 | Prefabricated stainless steel crown - primary tooth | 8.2% | 5,950 | 4,126 | $6.78M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 7.0% | 2,587 | 2,394 | $5.79M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 3.1% | 32,360 | 18,625 | $2.61M |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 2.9% | 1,116 | 827 | $2.40M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.7% | 3,180 | 3,155 | $2.28M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.4% | 9,237 | 8,895 | $1.98M |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.6% | 2,934 | 2,848 | $1.34M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 3,863 | 3,514 | $1.03M |
| V5261 | Hearing aid, digital, binaural, bte | 1.2% | 181 | 177 | $970K |
515 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.1% | 26,403 | $875K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,863 | $816K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 3,922 | $762K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,382 | $712K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,411 | $680K |
| 95782 | <1% | 408 | $642K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 5,664 | $632K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 46,575 | $533K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,187 | $494K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 276 | $422K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 358 | $404K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,088 | $395K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 20,941 | $381K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 634 | $375K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,871 | $330K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 26,892 | $325K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 543 | $317K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,296 | $278K |
| 93320 | <1% | 3,863 | $276K | |
| 76770 | <1% | 2,663 | $261K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,100 | $258K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13,070 | $252K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 3,734 | $249K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 12,043 | $249K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,717 | $245K |
| 64642 | <1% | 621 | $215K | |
| 80053 | Comprehensive metabolic panel | <1% | 7,687 | $201K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 1,207 | $197K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,352 | $197K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,146 | $190K |
| J3490 | Unclassified drugs | <1% | 24,242 | $187K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 299 | $186K |
| 92567 | <1% | 7,362 | $186K | |
| 82977 | <1% | 11,578 | $183K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,204 | $181K |
| 94010 | <1% | 7,976 | $179K | |
| 72141 | <1% | 334 | $174K | |
| 84439 | <1% | 11,173 | $174K | |
| D2390 | <1% | 996 | $173K | |
| 80076 | <1% | 8,402 | $169K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 15,544 | $168K |
| 70543 | <1% | 177 | $167K | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 2,070 | $159K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 399 | $155K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 3,713 | $154K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,997 | $150K |
| 72082 | <1% | 1,804 | $147K | |
| 54161 | <1% | 132 | $147K | |
| 86832 | <1% | 601 | $146K | |
| 81229 | <1% | 247 | $140K | |
| 83735 | <1% | 10,639 | $140K | |
| 80061 | Lipid panel | <1% | 4,804 | $136K |
| 82784 | <1% | 3,592 | $136K | |
| 42830 | <1% | 175 | $136K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,099 | $129K |
| 86003 | <1% | 1,214 | $128K | |
| 87799 | <1% | 1,441 | $126K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 306 | $126K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,935 | $124K |
| 86833 | <1% | 569 | $123K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,266 | $122K |
| 95812 | <1% | 1,198 | $119K | |
| 80050 | General health panel | <1% | 1,312 | $119K |
| 88230 | <1% | 340 | $114K | |
| 92587 | <1% | 1,721 | $110K | |
| 76885 | <1% | 510 | $109K | |
| 95816 | <1% | 3,237 | $109K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 31,855 | $108K |
| S9470 | Nutritional counseling, dietitian visit | <1% | 2,303 | $106K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,954 | $105K |
| 96040 | <1% | 1,488 | $104K | |
| 72146 | <1% | 272 | $100K | |
| 93975 | <1% | 1,122 | $96K | |
| J0475 | Injection, baclofen, 10 mg | <1% | 907 | $96K |
| 77073 | <1% | 1,645 | $96K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,056 | $95K |
| 96409 | <1% | 495 | $89K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,300 | $87K |
| 74018 | <1% | 2,854 | $86K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 303 | $86K |
| 80197 | <1% | 2,766 | $86K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 346 | $85K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,185 | $84K |
| V5160 | Dispensing fee, binaural | <1% | 200 | $83K |
| 80069 | <1% | 2,873 | $82K | |
| 84460 | <1% | 6,405 | $82K | |
| 87497 | <1% | 719 | $80K | |
| 85652 | <1% | 11,462 | $79K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,922 | $79K |
| 82728 | <1% | 4,005 | $79K | |
| 96415 | <1% | 1,048 | $79K | |
| 84100 | <1% | 6,880 | $76K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,154 | $75K |
| 73610 | <1% | 2,179 | $74K | |
| 84450 | <1% | 5,999 | $73K | |
| 86140 | <1% | 9,328 | $71K | |
| 72081 | <1% | 1,461 | $71K | |
| 86360 | <1% | 650 | $69K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,517 | $68K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,451 | $68K |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 1,581 | $65K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,638 | $65K |
| 69610 | <1% | 48 | $63K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,097 | $62K |
| 73560 | <1% | 1,687 | $61K | |
| 54830 | <1% | 56 | $59K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,280 | $57K |
| 97162 | <1% | 441 | $57K | |
| 94664 | <1% | 1,970 | $56K | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 853 | $55K |
| G0008 | Administration of influenza virus vaccine | <1% | 508 | $54K |
| 97166 | <1% | 441 | $53K | |
| 84403 | <1% | 883 | $53K | |
| 92557 | <1% | 731 | $53K | |
| 82565 | <1% | 4,500 | $53K | |
| 92611 | <1% | 542 | $52K | |
| 86480 | <1% | 392 | $51K | |
| 81243 | <1% | 274 | $51K | |
| 73630 | <1% | 2,183 | $50K | |
| 54640 | <1% | 163 | $50K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 878 | $49K |
| 43193 | <1% | 49 | $49K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 2,711 | $49K |
| 86618 | <1% | 904 | $49K | |
| 93325 | <1% | 1,652 | $49K | |
| 82962 | <1% | 8,481 | $48K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 434 | $48K |
| 83970 | <1% | 567 | $48K | |
| 86359 | <1% | 650 | $48K | |
| 90674 | <1% | 1,012 | $47K | |
| 95700 | <1% | 762 | $47K | |
| 36430 | <1% | 400 | $47K | |
| 83655 | <1% | 2,192 | $45K | |
| 44970 | <1% | 26 | $45K | |
| 93226 | <1% | 511 | $44K | |
| 85045 | <1% | 4,193 | $44K | |
| 84305 | <1% | 813 | $44K | |
| 73564 | <1% | 752 | $43K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 22,072 | $41K |
| 82139 | <1% | 736 | $40K | |
| 87631 | <1% | 147 | $40K | |
| 86355 | <1% | 649 | $40K | |
| 86357 | <1% | 650 | $40K | |
| 73090 | <1% | 2,208 | $40K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 858 | $40K |
| 88185 | <1% | 250 | $39K | |
| 84402 | <1% | 603 | $38K | |
| 73521 | <1% | 848 | $38K | |
| 82570 | <1% | 2,576 | $37K | |
| V5257 | Hearing aid, digital, monaural, bte | <1% | 12 | $37K |
| 81001 | <1% | 13,309 | $37K | |
| 83540 | <1% | 2,653 | $36K | |
| 70544 | <1% | 128 | $36K | |
| 86923 | <1% | 424 | $35K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 721 | $35K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 16,519 | $35K |
| D2330 | <1% | 764 | $35K | |
| 74230 | <1% | 535 | $35K | |
| 82607 | <1% | 1,830 | $35K | |
| 76775 | <1% | 298 | $34K | |
| 76536 | <1% | 364 | $34K | |
| 73590 | <1% | 1,244 | $34K | |
| 83615 | <1% | 2,340 | $33K | |
| 97165 | <1% | 243 | $33K | |
| 95713 | <1% | 528 | $33K | |
| 82024 | <1% | 400 | $33K | |
| A4606 | Oxygen probe for use with oximeter device, replacement | <1% | 1,016 | $32K |
| 77072 | <1% | 1,327 | $32K | |
| 82785 | <1% | 906 | $32K | |
| 84520 | <1% | 4,029 | $32K | |
| 73100 | <1% | 1,302 | $31K | |
| 85730 | <1% | 3,031 | $31K | |
| 82247 | <1% | 3,295 | $31K | |
| 92555 | <1% | 2,164 | $31K | |
| P9021 | Red blood cells, each unit | <1% | 207 | $31K |
| 83021 | <1% | 595 | $30K | |
| 83001 | <1% | 807 | $30K | |
| 92583 | <1% | 373 | $30K | |
| 88262 | <1% | 91 | $29K | |
| 83002 | <1% | 810 | $29K | |
| D1510 | <1% | 377 | $29K | |
| 82157 | <1% | 505 | $28K | |
| 86317 | <1% | 212 | $28K | |
| 84270 | <1% | 484 | $27K | |
| 84075 | <1% | 3,022 | $27K | |
| 74019 | <1% | 1,331 | $27K | |
| 76506 | <1% | 232 | $27K | |
| 74183 | <1% | 37 | $26K | |
| 87070 | <1% | 2,252 | $26K | |
| 85610 | <1% | 3,562 | $26K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 170 | $26K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,258 | $25K |
| 74240 | <1% | 286 | $25K | |
| 82627 | <1% | 536 | $25K | |
| 93225 | <1% | 543 | $25K | |
| 95990 | <1% | 213 | $25K | |
| 73070 | <1% | 1,071 | $25K | |
| 82550 | <1% | 1,882 | $25K | |
| 83498 | <1% | 511 | $24K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,480 | $24K |
| 82248 | <1% | 2,482 | $24K | |
| 96450 | <1% | 168 | $24K | |
| 72158 | <1% | 41 | $24K | |
| 97161 | <1% | 186 | $24K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 466 | $24K |
| 85246 | <1% | 362 | $24K | |
| 84146 | <1% | 462 | $23K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 249 | $23K |
| 82670 | <1% | 482 | $23K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 731 | $22K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,512 | $22K |
| 83880 | <1% | 460 | $21K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,748 | $21K |
| 92552 | <1% | 1,112 | $21K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 513 | $21K |
| 82533 | <1% | 590 | $20K | |
| 83550 | <1% | 2,585 | $20K | |
| J1815 | Injection, insulin, per 5 units | <1% | 110 | $20K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 681 | $20K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,750 | $19K |
| 97167 | <1% | 133 | $19K | |
| 85245 | <1% | 286 | $19K | |
| 84481 | <1% | 662 | $18K | |
| 95951 | <1% | 37 | $18K | |
| 85247 | <1% | 272 | $18K | |
| 82947 | <1% | 2,380 | $17K | |
| 85576 | <1% | 265 | $17K | |
| 83525 | <1% | 411 | $17K | |
| 31624 | <1% | 49 | $17K | |
| 87081 | <1% | 2,137 | $17K | |
| 86800 | <1% | 409 | $17K | |
| 93017 | <1% | 170 | $17K | |
| 82542 | <1% | 454 | $17K | |
| 76800 | <1% | 146 | $17K | |
| 72156 | <1% | 37 | $16K | |
| V5266 | Battery for use in hearing device | <1% | 1,574 | $16K |
| 83690 | <1% | 2,564 | $16K | |
| 93531 | <1% | 12 | $16K | |
| 71555 | <1% | 28 | $16K | |
| 83921 | <1% | 610 | $16K | |
| 88341 | <1% | 203 | $15K | |
| 82105 | <1% | 445 | $15K | |
| 88184 | <1% | 233 | $15K | |
| 84630 | <1% | 753 | $15K | |
| 86850 | <1% | 1,392 | $15K | |
| 92553 | <1% | 444 | $15K | |
| 72157 | <1% | 25 | $14K | |
| 82525 | <1% | 791 | $14K | |
| 94060 | <1% | 517 | $14K | |
| 72170 | <1% | 708 | $14K | |
| 31575 | <1% | 14 | $14K | |
| 49452 | <1% | 13 | $14K | |
| 88342 | <1% | 406 | $14K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 98 | $14K |
| 93321 | <1% | 356 | $13K | |
| 82803 | <1% | 1,056 | $13K | |
| 77074 | <1% | 186 | $13K | |
| 87186 | <1% | 1,282 | $13K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 212 | $13K |
| 86160 | <1% | 221 | $13K | |
| 73552 | <1% | 521 | $13K | |
| 83516 | <1% | 423 | $13K | |
| 73620 | <1% | 564 | $12K | |
| 82610 | <1% | 408 | $12K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 13 | $12K |
| 84681 | <1% | 261 | $12K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 474 | $12K |
| 96411 | <1% | 89 | $12K | |
| 86038 | <1% | 374 | $12K | |
| 76870 | <1% | 313 | $12K | |
| 92591 | <1% | 189 | $12K | |
| 70480 | <1% | 70 | $12K | |
| 31622 | <1% | 31 | $11K | |
| 69210 | <1% | 12 | $11K | |
| 86001 | <1% | 607 | $11K | |
| 73130 | <1% | 729 | $11K | |
| 80299 | <1% | 439 | $11K | |
| 97163 | <1% | 85 | $11K | |
| 86664 | <1% | 388 | $11K | |
| 94621 | <1% | 80 | $11K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,047 | $11K |
| 73562 | <1% | 501 | $11K | |
| 82040 | <1% | 1,993 | $11K | |
| 88249 | <1% | 28 | $11K | |
| 64643 | <1% | 277 | $10K | |
| 51600 | <1% | 124 | $10K | |
| 94761 | <1% | 167 | $10K | |
| 83919 | <1% | 282 | $10K | |
| 72040 | <1% | 729 | $10K | |
| 84155 | <1% | 1,503 | $10K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,234 | $10K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $10K |
| 73600 | <1% | 393 | $10K | |
| 92556 | <1% | 291 | $10K | |
| 86376 | <1% | 559 | $9K | |
| J7699 | Noc drugs, inhalation solution administered through dme | <1% | 224 | $9K |
| D2331 | <1% | 125 | $9K | |
| 85240 | <1% | 356 | $9K | |
| 86665 | <1% | 393 | $9K | |
| 86663 | <1% | 386 | $9K | |
| 73110 | <1% | 767 | $9K | |
| 77075 | <1% | 297 | $9K | |
| 84590 | <1% | 325 | $9K | |
| 73030 | <1% | 381 | $9K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,448 | $9K |
| 80195 | <1% | 275 | $9K | |
| 82746 | <1% | 514 | $8K | |
| 82150 | <1% | 1,430 | $8K | |
| 93971 | <1% | 75 | $8K | |
| 92595 | <1% | 421 | $8K | |
| 87077 | <1% | 878 | $8K | |
| 80051 | <1% | 534 | $8K | |
| 86901 | <1% | 1,285 | $8K | |
| 86900 | <1% | 1,395 | $8K | |
| 70360 | <1% | 352 | $8K | |
| 70486 | <1% | 230 | $8K | |
| 86255 | <1% | 195 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 742 | $7K |
| 84550 | <1% | 672 | $7K | |
| 83993 | <1% | 195 | $7K | |
| 85018 | <1% | 1,276 | $7K | |
| 93308 | <1% | 180 | $7K | |
| 80183 | <1% | 301 | $7K | |
| 74270 | <1% | 133 | $7K | |
| 73080 | <1% | 691 | $7K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 4,777 | $7K |
| 82747 | <1% | 173 | $7K | |
| 73140 | <1% | 439 | $7K | |
| 84156 | <1% | 752 | $7K | |
| 84480 | <1% | 422 | $7K | |
| 82652 | <1% | 227 | $7K | |
| 73000 | <1% | 337 | $7K | |
| 84446 | <1% | 299 | $6K | |
| 74455 | <1% | 104 | $6K | |
| 84478 | <1% | 642 | $6K | |
| 82180 | <1% | 600 | $6K | |
| 92585 | <1% | 169 | $6K | |
| 87147 | <1% | 1,047 | $6K | |
| 93304 | <1% | 135 | $6K | |
| 86235 | <1% | 38 | $6K | |
| 86803 | <1% | 163 | $6K | |
| 73060 | <1% | 354 | $6K | |
| 86702 | <1% | 327 | $6K | |
| 72100 | <1% | 240 | $5K | |
| 86780 | <1% | 241 | $5K | |
| 86617 | <1% | 178 | $5K | |
| 86706 | <1% | 216 | $5K | |
| 86701 | <1% | 327 | $5K | |
| 87340 | <1% | 198 | $5K | |
| 76942 | <1% | 264 | $5K | |
| 82330 | <1% | 1,138 | $5K | |
| 80175 | <1% | 233 | $5K | |
| 81025 | <1% | 1,811 | $5K | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 1,710 | $5K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 171 | $5K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 53 | $5K |
| 82726 | <1% | 121 | $5K | |
| 85732 | <1% | 318 | $5K | |
| 80177 | <1% | 268 | $5K | |
| 95716 | <1% | 76 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,851 | $5K |
| 88313 | <1% | 252 | $4K | |
| 84295 | <1% | 1,261 | $4K | |
| 83605 | <1% | 345 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 127 | $4K |
| 87390 | <1% | 325 | $4K | |
| 82390 | <1% | 208 | $4K | |
| 76882 | <1% | 323 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 26 | $4K |
| 73700 | <1% | 38 | $4K | |
| 85384 | <1% | 209 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 679 | $4K |
| 82310 | <1% | 331 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,564 | $4K |
| 87040 | <1% | 506 | $4K | |
| 94760 | <1% | 598 | $4K | |
| 0001A | <1% | 127 | $3K | |
| 82085 | <1% | 187 | $3K | |
| 70491 | <1% | 25 | $3K | |
| 86060 | <1% | 358 | $3K | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 171 | $3K |
| 74220 | <1% | 85 | $3K | |
| P9058 | Red blood cells, leukocytes reduced, cmv-negative, irradiated, each unit | <1% | 32 | $3K |
| V5241 | Dispensing fee, monaural hearing aid, any type | <1% | 12 | $3K |
| 89051 | <1% | 314 | $3K | |
| 72070 | <1% | 175 | $3K | |
| 85027 | <1% | 237 | $3K | |
| 85660 | <1% | 270 | $3K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 5,863 | $3K |
| J9370 | Vincristine sulfate, 1 mg | <1% | 1,387 | $3K |
| 77080 | <1% | 28 | $3K | |
| 86704 | <1% | 92 | $3K | |
| 80203 | <1% | 121 | $3K | |
| 92594 | <1% | 142 | $3K | |
| 82140 | <1% | 294 | $2K | |
| 85014 | <1% | 1,298 | $2K | |
| 82104 | <1% | 60 | $2K | |
| 87329 | <1% | 130 | $2K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 61 | $2K |
| 84132 | <1% | 1,134 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 115 | $2K |
| 83018 | <1% | 39 | $2K | |
| 82373 | <1% | 130 | $2K | |
| 87102 | <1% | 153 | $2K | |
| 80164 | <1% | 71 | $2K | |
| 86769 | <1% | 114 | $2K | |
| 0071A | <1% | 58 | $2K | |
| 86902 | <1% | 75 | $2K | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | <1% | 239 | $2K |
| 70250 | <1% | 95 | $2K | |
| 82340 | <1% | 108 | $2K | |
| 82945 | <1% | 258 | $2K | |
| 94644 | <1% | 436 | $2K | |
| 76937 | <1% | 168 | $2K | |
| 84157 | <1% | 256 | $2K | |
| 83930 | <1% | 285 | $2K | |
| 88108 | <1% | 338 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 41 | $2K |
| 82465 | <1% | 306 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,792 | $1K |
| 92626 | <1% | 25 | $1K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 17 | $1K |
| 86592 | <1% | 250 | $1K | |
| 87807 | <1% | 1,788 | $1K | |
| 84484 | <1% | 374 | $1K | |
| S0080 | Injection, pentamidine isethionate, 300 mg | <1% | 15 | $1K |
| 86644 | <1% | 41 | $1K | |
| 84703 | <1% | 114 | $1K | |
| 80074 | <1% | 13 | $1K | |
| 72020 | <1% | 96 | $1K | |
| 85540 | <1% | 59 | $1K | |
| 87045 | <1% | 138 | $1K | |
| 80180 | <1% | 31 | $952.37 | |
| 87046 | <1% | 139 | $952.15 | |
| 92579 | <1% | 13 | $952.14 | |
| 86708 | <1% | 24 | $944.46 | |
| 92588 | <1% | 12 | $917.56 | |
| 88307 | <1% | 94 | $895.85 | |
| 86977 | <1% | 26 | $851.61 | |
| 76857 | <1% | 28 | $820.63 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 570 | $808.67 |
| 85397 | <1% | 13 | $778.41 | |
| 82103 | <1% | 17 | $766.29 | |
| 84436 | <1% | 44 | $736.74 | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,052 | $697.55 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 54 | $650.40 |
| 89230 | <1% | 89 | $635.23 | |
| 86713 | <1% | 25 | $611.77 | |
| 85379 | <1% | 207 | $596.30 | |
| C9399 | Unclassified drugs or biologicals | <1% | 266 | $593.56 |
| 85520 | <1% | 34 | $562.90 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 12 | $562.23 |
| 84145 | <1% | 341 | $554.58 | |
| 83090 | <1% | 16 | $528.97 | |
| 86215 | <1% | 24 | $522.07 | |
| 0002A | <1% | 14 | $480.00 | |
| 88312 | <1% | 25 | $478.82 | |
| 83003 | <1% | 15 | $464.26 | |
| 86308 | <1% | 159 | $392.08 | |
| 83935 | <1% | 70 | $388.21 | |
| 88304 | <1% | 296 | $388.19 | |
| 84244 | <1% | 15 | $383.52 | |
| 84585 | <1% | 12 | $329.92 | |
| 87400 | <1% | 13 | $292.33 | |
| 87075 | <1% | 25 | $290.18 | |
| 73592 | <1% | 29 | $275.31 | |
| 83864 | <1% | 13 | $267.30 | |
| 82270 | <1% | 50 | $220.27 | |
| 83150 | <1% | 12 | $206.19 | |
| 82010 | <1% | 81 | $201.20 | |
| 87015 | <1% | 26 | $191.24 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,184 | $170.40 |
| 99152 | <1% | 144 | $152.93 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 255 | $132.53 |
| 86880 | <1% | 13 | $122.92 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 46 | $98.44 |
| 85041 | <1% | 12 | $80.17 | |
| 99151 | <1% | 57 | $69.04 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 10,547 | $65.72 |
| 85048 | <1% | 219 | $63.13 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 130 | $54.00 |
| 82948 | <1% | 866 | $49.10 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 380 | $41.50 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 505 | $38.72 |
| 94645 | <1% | 103 | $36.36 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 89 | $27.95 |
| J9250 | Methotrexate sodium, 5 mg | <1% | 113 | $18.92 |
| 88300 | <1% | 674 | $14.22 | |
| 80329 | <1% | 135 | $7.73 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 61 | $7.02 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 512 | $5.46 |
| 91300 | <1% | 161 | $1.08 | |
| 91307 | <1% | 54 | $0.42 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 275 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 804 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 1,577 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 88 | $0.00 |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 41 | $0.00 |
| J9260 | Injection, methotrexate sodium, 50 mg | 0% | 46 | $0.00 |
| 81002 | 0% | 71 | $0.00 | |
| 90715 | 0% | 37 | $0.00 | |
| 90675 | 0% | 39 | $0.00 | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | 0% | 27 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 80 | $0.00 |
| 90661 | 0% | 218 | $0.00 | |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | 0% | 55 | $0.00 |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | 0% | 1,733 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 478 | $0.00 |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 0% | 66 | $0.00 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 0% | 128 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 62 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 28 | $0.00 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | 0% | 25 | $0.00 |
| 41899 | Unlisted procedure, dentoalveolar structures | 0% | 25 | $0.00 |
| J9312 | Injection, rituximab, 10 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILFONG, MARIO (CFO)
| Provider | Location | Paid |
|---|---|---|
| Upmc Children's Hospital of Pittsburgh | Sewickley, PA | $40K |
| Upmc Children's Hospital of Pittsburgh | Pittsburgh, PA | $8K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.